$ cat ./records/iavi-hiv-vaccine-trials-backed-by-gates-foundation-cavd-show-firs-2022.txt
IAVI HIV Vaccine Trials Backed by Gates Foundation CAVD Show First Proof-of-Concept for Broadly Neutralising Antibody Priming
[RECORD.TXT] · cat --full
Results from IAVI G001, G002, and G003 clinical trials — supported through the Gates Foundation's $287 million Collaboration for AIDS Vaccine Discovery (CAVD) network — showed that targeted protein vaccines can activate rare germline precursor immune cells for HIV broadly neutralising antibodies. IAVI G003 enrolled participants in South Africa and Rwanda — the first African bNAb-priming trial results — validating the stepwise rational vaccine design approach against a pathogen affecting 38 million people globally.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Grants Pfizer $100 Million for Group B Streptococcus Maternal Vaccine Phase 3 and LMIC Access
Next →
Gates Foundation Commits $50 Million to Vir Biotechnology for HIV Broadly Neutralising Antibody Functional Cure
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.